Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Sells 15,000 Shares Under 10b5-1 Trading Plan

CRISPR Therapeutics CEO Samarth Kulkarni sold 15,000 common shares at a weighted average price of $55.1043, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Samarth Kulkarni, CEO of CRISPR Therapeutics, sold 15,000 common shares on December 2, 2024.
• The shares were sold at a weighted average price of $55.1043.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2024.
• The transactions occurred at prices ranging from $55.00 to $55.33 per share.
• Following the transaction, Kulkarni directly owns 181,540 common shares and indirectly owns 85,622 shares through the Kulkarni 2023 GRAT.

Sentiment

Score: 5

Explanation: The document reflects a routine insider transaction under a pre-arranged plan, which is neither particularly positive nor negative. It's a neutral event from an investment perspective.

Risks

• Sales by company insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 trading plans is a standard practice for executives to manage their stock sales while avoiding accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Vertex Pharmaceuticals and BioMarin Pharmaceutical.
• These plans allow insiders to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The volume of shares sold by Kulkarni is relatively small compared to the total outstanding shares of CRISPR Therapeutics, which is typical for routine insider sales.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but the pre-planned nature of the transaction should mitigate any significant negative reaction.

Key Dates

Keywords

CRISPR Therapeutics, Samarth Kulkarni, insider trading, stock sale, Rule 10b5-1, executive, share transaction